Tikva’s published paper on enhancing allogeneic T-cell persistence and efficacy with overexpression of an Engineered SerpinB9

Research Article - Overexpression of an Engineered SerpinB9 Enhances Allogeneic T-Cell Persistence and Efficacy

SINGAPORE – 06 Jun 2024 – Tikva Allocell scientists publish scientific article in Cancer Immunology Research on enhancing allogeneic T-cell persistence and efficacy with overexpression of an Engineered SerpinB9.

Allogeneic chimeric antigen receptor (CAR)-expressing T cells offer many advantages over autologous therapies, but their benefits are curtailed by graft-versus-host disease (GvHD) and elimination by recipient immune cells. Moreover, just as with autologous therapies, allogeneic CAR T cells are susceptible to activation-induced cell death (AICD).

This study conducted by Tikva Allocell Scientists shows that the overexpression of an engineered serine protease inhibitor molecule increases CAR EBVST tolerance against both allogeneic rejection (allo-rejection) and activation induced cell death.

This SerpinB9 modification will thus further strengthen Tikva’s allogeneic CAR EBVST platform as a safe and efficacious off-the-shelf cell therapy against solid tumors.

Lionel Liow, PhD

Director, molecular biology

Lionel is the Director of the Molecular Biology Team at Tikva Allocell. He brings considerable molecular cell biology experience, specifically in T cell receptor. CAR and antibody discovery and engineering. He is also the inventor of 8 patents and key author on 5 publications.

Share the Post:

Related Posts